Latest Orna Therapeutics News & Updates

See the latest news and media coverage for Orna Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Orna Therapeutics

Developer of engineered circular RNA therapeutics

ornatx.com
Headquarters
Watertown, United States
Founded year
2019
Company type
Private company
Number of employees
125–200

Last updated

Latest news about Orna Therapeutics

In short: Orna Therapeutics was acquired by Eli Lilly and Company in a deal valued at up to $2.4 billion to advance in vivo cell therapies.

Company announcements

Orna Therapeutics

Orna Therapeutics presents preclinical data on in vivo CAR programs

Data supports anti-CD19 ORN-252 for autoimmune diseases and anti-BCMA for oncology, shown at ASH 2025. Plans CTA submission by end 2025.

Unlock all announcements with a

Media coverage

The Wall Street Journal

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion

Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash. Eli Lilly on Monday said...

Unlock all articles with a

Never miss news about Orna Therapeutics

Track Orna Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Orna Therapeutics competitors & trending companies

Browse news for competitors to Orna Therapeutics and other trending companies.